Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19 | MicrobiomeTrials← Back to trialsNCT06703034
Characterization of the IFN-I Response in Subjects Who Experienced Severe or Mild Forms of COVID-19
RecruitingNAINTERVENTIONAL
Trial Details
Start: 2024-12-02Est. Completion: 2027-06
Enrollment target: 134 participants Locations- Hospices Civils de Lyon - Hôpital de la Croix-Rousse, Lyon, France
Other microbiome trials you might be interested in
IsolationAnxietyHealth Care UtilizationSickle Cell DiseasePain
Background:
Sickle cell disease (SCD) is a chronic illness. It affects about 100,000 people in the United States. Peopl…
Bethesda, United StatesCompleted May 18, 2022
Coronavirus Infection
Since the last 3 months the world copes with the novel coronavirus disease : Covid-19 emerged in China in the end of 201…
Limoges, FranceCompleted Jul 2020
Post-COVIDPOST-Covid 19Post-COVID Conditions
Fatigue, cognitive problems, post-exertional malaise (PEM) and postural orthostatic tachycardia syndrome (POTS) are comm…
Amsterdam-Zuidoost, NetherlandsEst. completion Dec 31, 2027